OncoCyteOCX
Market Cap: $42.6M
About: OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.
Employees: 46
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
60% more capital invested
Capital invested by funds: $13.2M [Q1] → $21.1M (+$7.91M) [Q2]
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
0.97% less ownership
Funds ownership: 54.39% [Q1] → 53.42% (-0.97%) [Q2]
4% less funds holding
Funds holding: 25 [Q1] → 24 (-1) [Q2]
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Needham Mike Matson 64% 1-year accuracy 72 / 113 met price target | 33%upside $4.25 | Buy Reiterated | 9 Aug 2024 |
Financial journalist opinion
Based on 3 articles about OCX published over the past 30 days